Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 10/20 | 0.46 |
| ▸ | CDK2 | P24941 | 10/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833370 | 0.83 | JAK2 (0.36) | MAP2K1PKM | |
| SCHEMBL4830893 | 0.81 | MAP2K1 (0.51) | MAP2K1CCNE1CDK2MTNR1AGPR84 | |
| SCHEMBL4831382 | 0.81 | BRAF (0.47) | MAP2K1CDK2BRAF | |
| SCHEMBL4829642 | 0.81 | ADORA2A (0.44) | ADORA2ACDC7 | |
| SCHEMBL8290732 | 0.81 | MAP2K1 (0.40) | MAP2K1CCNE1CDK2MTNR1AGPR84 | |
| SCHEMBL4831235 | 0.81 | AXL (0.43) | MAP2K1CDK2BRAF | |
| SCHEMBL14002360 | 0.81 | MAP2K1 (0.53) | MAP2K1CCNE1CDK2MTNR1AGPR84 | |
| SCHEMBL4829366 | 0.78 | CTNNB1 (0.40) | ADORA2A | |
| SCHEMBL4828071 | 0.77 | AXL (0.39) | MAP2K1CDK2BRAF | |
| SCHEMBL4828081 | 0.77 | DYRK1A (0.39) | MAP2K1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | MAP2K1 403/4885CCNE1 1053/4885CDK2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.